prioriti review week januari
may miss past week
 realli valu time case miss anyth provid quick summari major event past eek
key event atch upcom eek also link research model applic highlight
frequent inbound question debat topic come investor minut read pleas let us
european patent offic board vote revok alexion soliri eu formul patent anonym third parti
challeng patent hile alexion indic ould need review ritten decisionnot expect eeksit ould
like appeal process like take year meantim eu patent applic composit matter method
use on-going thought eu soliri patent setback
vertex interim cfo ian smith dismiss dismiss reportedli due violat code conduct
relat vertex underli financi perform paul silva vertex svp corpor control chief account offic ill
becom interim cfo search replac previou cfo tom graney step dow decemb pursu
anoth opportun thought departur
allergan report posit top-lin data phase rituxan biosimilar studi studi abp biosimilar
roche/ rituxan met primari endpoint pk similar patient ith moderate-to-serv rheumatoid arthriti
safeti profil immunogen abp ere report similar rituxan anoth studi non-hodgkin lymphoma
on-going ith design support regulatori approv global
uk recommend gilead yescarta r/r dlbcl draft guidanc recommend yescarta option r/r dlbcl pmbcl
adult ho fail system therapi updat follow nice initi neg guidanc last august
european commiss approv vertex orkambi label expans includ homozyg children orkambi
previous indic children older ith homozyg background
uk recommend bristol opdivo/yervoy combo adjuv melanoma decis base data phase
stage iiib/c iv melanoma follow ing surgic resect
european commiss approv expand indic amgen blincyto indic includ philadelphia chromosom
neg b-cell precursor first second complet remiss ith mrd fda approv indic march
phase blast trial provid data support applic
fda accept merck snda anti-hiv doravirine-bas therapi pifeltro delstrigo approv ould expand use
pifeltro doravirin delstrigo doravirine/ lamivudine/ tdf virally-suppress hiv posit patient sw itch regimen pdufa
sept
vertex licens two merck kgaa gene-edit asset deal tw dna-depend protein kinas dna-pk inhibitor
formerli unidentifi pre-clin asset cover six specif genetic-bas diseas asset ere acquir
merck vertex per term agreement merck ill receiv undisclos up-front payment mileston
royalti merck also retain right develop diseas area although vertex option add addit
ironwood announc board director compani cyclerion post-spin name biographi new board
pleas see link spin-off remain track complet thought spin-off see ironw ood pharmaceut
thought call
biohaven receiv may proceed letter fda candid novel myeloperoxidas inhibitor
compani advanc treatment multipl system atrophi biohaven licens drug astrazeneca hich
origin file ind prompt former appli reactiv applic biohaven plan initi phase
vertex licens two merck kgaa gene-edit asset deal tw dna-depend protein kinas dna-pk inhibitor
formerli unidentifi pre-clin asset cover six specif genetic-bas diseas asset ere acquir
merck vertex per term agreement merck ill receiv undisclos up-front payment mileston
royalti merck also retain right develop indic although vertex option add addit diseas
first patient dose itacitinib gvhd studi studi ill evalu inhibitor itacitinib combin
 ith corticosteroid vs corticosteroid alon moderate-to-sever chronic gvhd target gvhd ith multipl approach
includ jakafi ith file phase data anticip itacitinib ith phase
expect thought jakafi data
ironwood initi phase sad/mad iw solubl guanyl cyclas stimul capabl enter central
nervou system develop serious/orphan diseas program one sgc program spin-off cyclerion plan
advanc
leav aimovig cover drug list announc compani ill includ amgen aimovig prefer drug list
 ill instead add compet drug teva ajovi emgal announc provid headw ind aimovig due
numer patient ho reli access medic coverag list
proprietari research past week includ coverag earn
inc thought call
bristol-my squibb thought call
johnson johnson thought call
client ask
investor ask follow ing topic phone call email in-person market meet
much eros expect humira ou miss low ere ou humira
sale expect declin -from previous investor concern potenti steeper eros due
earli stage biosimilar launch yet get good handl like share loss note
project subject revis think biosimilar eros like steeper model declin ever
expect continu grow th us humira busi biosimilar competit hit
impact soliri patent decis alexion eu commerci prospect despit unsurpris setback
european patent offic panel vote revok soliri eu formul patent dont see materi impact alexion
eu busi betw een expect appeal pend potenti stronger posit ith composit matter method
use soliri patent orphan drug design exclus prevent biosimilar competit ahu gmg
pnh patient sw itch ultomiri anticip approv think alexion invest case
remain strong support overw eight rate
implic vertex departur view involv extern counsel termin
earli retir underscor serious violat notabl seem us person natur ith
new risk compani fundament inde concern import vertex-specif issu cystic fibrosi cf
data integr histor financi guidanc strategi though vertex lose import face compani
watch week ahead
clinic trial read-out regulatori event expect near-term
ultomiri phase data ahu due earli
keytruda phase data classic hodgkin lymphoma due
selonsertib phase data nash due
filgotinib phase data rheumatoid arthriti due
phase data cf due
let us know question comment geoff greg scott jason olivia
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
materi conflict barclay bank plc and/or affili serv financi advisor merck co nyse relat
announc definit purchas agreement hich merck co nyse ill acquir antelliq group
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur
issuer previou month
 employe non-execut director barclay bank plc and/or affili director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic
issuer ithin next month
fa barclay bank plc and/or affili benefici ow ns class equiti secur issuer calcul
fb barclay bank plc and/or affili benefici ow ns long posit class equiti secur
issuer calcul accord ith eu regul
fc barclay bank plc and/or affili benefici ow ns short posit class equiti secur
issuer calcul accord ith eu regul
gd one analyst fundament credit coverag team member household financi interest
debt equiti secur issuer
ge one analyst fundament equiti coverag team member household financi interest
debt equiti secur issuer
 issuer benefici ow ns class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement ith issuer provis financi servic barclay
bank plc and/or affili
 barclay bank plc and/or affili liquid provid and/or trade regularli secur issuer and/or
 barclay bank plc and/or affili receiv non-invest bank relat compens includ compens
brokerag servic applic issuer ithin past month
 issuer past month invest bank client barclay bank plc and/or affili
issuer past month non-invest bank client secur relat servic barclay
bank plc and/or affili
 issuer past month non-invest bank client non-secur relat servic
barclay bank plc and/or affili
use
 partner director offic barclay capit canada inc preced month provid servic subject
compani remuner normal cours invest advisori trade execut servic
 barclay bank plc and/or affili corpor broker issuer
 barclay capit canada inc and/or affili receiv compens invest bank servic issuer
issuer corpor broker barclay plc
barclay bank plc and/or affili provid equiti advisori servic issuer
 equiti secur canadian issuer includ subordin vote restrict share
 equiti secur canadian issuer includ non-vot restrict share
guid barclay fundament equiti research rate system
coverag analyst use rel rate system hich rate stock overw eight equal eight underw eight see
definit rel compani cover analyst team analyst deem
industri industri coverag univers see list compani compris particular industri coverag univers pleas
go http //publicresearch barclay com
addit stock rate provid industri view hich rate outlook industri coverag univers posit
neutral neg see definit rate system use term buy hold sell equival rate
system investor care read entir research report includ definit rate infer content
rate alon
overweight stock expect outperform unw eight expect total return industri coverag univers
equal weight stock expect perform line ith unw eight expect total return industri coverag univers
invest horizon
underweight stock expect under-perform unw eight expect total return industri coverag univers
rate suspend rate target price suspend temporarili due market event made coverag
impractic compli ith applic regul and/or firm polici certain circumst includ invest
barclay plc act advisori capac merger strateg transact involv compani
posit industri coverag univers fundamentals/valu improv
neutral industri coverag univers fundamentals/valu steadi neither improv deterior
neg industri coverag univers fundamentals/valu deterior
distribut rate
barclay equiti research compani coverag
assign overw eight rate hich purpos mandatori regulatori disclosur classifi buy
